{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:14:46Z","timestamp":1759961686700},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,3,15]],"date-time":"2010-03-15T00:00:00Z","timestamp":1268611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Aim:\u2002<\/jats:bold> To test whether treatment with celecoxib reduces the incidence of gastroduodenal ulcers compared to diclofenac in Asian patients with osteoarthritis (OA) or rheumatoid arthritis (RA) with minimal significant risk factors.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Patients with a clinical diagnosis of OA or RA of at least 3\u2003months were randomized to 12\u2003weeks of double\u2010blind treatment with celecoxib 100\u2003mg twice daily (<jats:italic>n<\/jats:italic>\u2003=\u2003440) or diclofenac 50\u2003mg twice daily (<jats:italic>n<\/jats:italic>\u2003=\u2003440). The primary outcome was the gastric and\/or duodenal ulcer rate at endpoint as determined by upper gastrointestinal endoscopy performed during the screening week, and at endpoint.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> There was no significant difference in the overall incidence of gastroduodenal ulcers at 12\u2010week endpoint for celecoxib compared to diclofenac (2.8%<jats:italic>vs.<\/jats:italic> 5.1%; Cochran\u2013Mantel\u2013Haenszel [CMH] \u03c7<jats:sup>2<\/jats:sup><jats:italic>P<\/jats:italic>\u2003=\u20030.083). However, there was a significantly lower incidence of gastric ulcers on celecoxib versus diclofenac (0.5%<jats:italic>vs.<\/jats:italic> 3.6%; CMH \u03c7<jats:sup>2<\/jats:sup><jats:italic>P<\/jats:italic>\u2003=\u20030.002). Approximately 59% of patients in both treatment groups had no visible gastric lesions at endpoint; and a similar proportion were found to have one or more erosions on celecoxib (<jats:italic>n<\/jats:italic>\u2003=\u200385; 21.4%) and diclofenac (<jats:italic>N<\/jats:italic>\u2003=\u200391; 23.3%). A survival analysis of time to ulcer was significant for gastric ulcers (log\u2010rank <jats:italic>P<\/jats:italic>\u2003=\u20030.004), but not for duodenal ulcers, or for gastroduodenal ulcers combined. Fewer patients reported at least one adverse event on celecoxib compared to diclofenac (42.4%<jats:italic>vs.<\/jats:italic> 50.3%; \u03c7<jats:sup>2<\/jats:sup>, 5.52; <jats:italic>P<\/jats:italic>\u2003=\u20030.019).<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> In Asian patients with minimal significant risk factors, treatment with celecoxib was associated with a modest but significantly reduced incidence of gastric ulcers at the end of 12\u2003weeks.<\/jats:p>","DOI":"10.1111\/j.1756-185x.2010.01463.x","type":"journal-article","created":{"date-parts":[[2010,3,15]],"date-time":"2010-03-15T09:55:31Z","timestamp":1268646931000},"page":"151-157","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12\u2010week trials in Chinese patients with osteoarthritis or rheumatoid arthritis"],"prefix":"10.1111","volume":"13","author":[{"given":"Raymond","family":"CHEUNG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tien\u2010Tsai","family":"CHENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"DONG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiao\u2010Yi","family":"LIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamchuen","family":"LAI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chak\u2010sing","family":"LAU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang","family":"FENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"PARSONS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,5,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00362-9"},{"key":"e_1_2_6_3_2","first-page":"804","article-title":"A meta\u2010analysis of severe upper gastrointestinal complications of nonsteroidal anti\u2010inflammatory drugs","volume":"29","author":"Ofman JJ","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07273-2"},{"key":"e_1_2_6_5_2","first-page":"96","article-title":"Epidemiological study on upper digestive injuries by non\u2010steroidal anti\u2010inflammatory drugs","volume":"31","author":"Shiokawa Y","year":"1991","journal-title":"J Jpn Rheum Assoc"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00776-007-1139-9"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16893-1"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0203-8"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.09.054"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103293441304"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60749-1"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350502"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1247"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.04.031"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.07.010"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00499.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.06.006"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1756-185X.2010.01463.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1756-185X.2010.01463.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T02:25:04Z","timestamp":1698719104000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1756-185X.2010.01463.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1756-185X.2010.01463.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1756-185x.2010.01463.x","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"2010-05-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}